Patient responses
| Patient no. . | Imatinib dose, mg . | Best cytogenetic response . | Best molecular response . | Time to detection of abnormality, mo . | Cytogenetic abnormality type . | No. of metaphases . | No. of times abnormality detected . | MDS . | Follow up abnormality detection, mo . | Survival from diagnosis, mo . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 800 | CCyR | CMR | 18 | t(X;17)(q22;q36) | 1 | 1 | No | 24 | 32 |
| 2 | 800 | CCyR | MMR | 12 | t(15;16)(q15;q24) | 1 | 1 | No | 18 | 30 |
| 3 | 800 | CCyR | CMR | 21 | t(11;17) | 1 | 1 | No | 12 | 33 |
| 4 | 800 | CCyR | MMR | 12 | +X | 1 | 1 | No | 12 | 24 |
| 5 | 800 | CCyR | MMR | 21 | −Y | 1 | 1 | No | 12 | 33 |
| 6 | 800 | CCyR | NA | 27 | del (20) (q11.2) | 1 | 1 | No | 12 | 39 |
| 7 | 400 | CCyR | NA | 21, 27 | del (7) (q22), +8 | 1, 6 | 1, 2 | No | 39, 33 | 60 |
| 8 | 400 | CCyR | MMR | 36 | del (13) (q12q22) | 2 | 1 | No | 15 | 51 |
| 9 | 400 | CCyR | NA | 24, 36 | +8, +6 | 2, 2 | 1, 2 | No | 33, 21 | 57 |
| 10 | 400 | CCyR | CMR | 15 | −Y | 4 | 1 | No | 45 | 60 |
| 11 | 400 | CCyR | MMR | 42 | −Y | 4 | 2 | No | 18 | 60 |
| 12 | 800 | CCyR | MMR | 6 | −Y | 4 | 1 | No | 6 | 12 |
| 13 | 400 | CCyR | MMR | 36 | −Y | 7 | 5 | No | 24 | 60 |
| 14 | 800 | CCyR | MMR | 24 | del (20) (q12) | 2 | 1 | No | 12 | 36 |
| 15 | 800 | CCyR | MMR | 9 | del (7) (q22q34) | 2 | 1 | No | 15 | 24 |
| 16 | 400 | PCyR | NA | 12 | +8 | 2 | 1 | No | 45 | 57 |
| 17 | 800 | mCyR | NA | 6 | −Y | 3 | 3 | No | 36 | 42 |
| 18 | 800 | PCyR | NA | 3 | −Y | 7 | 2 | No | 3 | 6 |
| 19 | 800 | CCyR | CMR | 24 | −Y | 4 | 1 | No | 24 | 48 |
| 20 | 800 | CCyR | MMR | 3 | −Y | 13 | 4 | No | 9 | 12 |
| 21 | 400 | CCyR | NA | 6 | −7 | 20 | 2 | Yes | 6 | 12 |
| Patient no. . | Imatinib dose, mg . | Best cytogenetic response . | Best molecular response . | Time to detection of abnormality, mo . | Cytogenetic abnormality type . | No. of metaphases . | No. of times abnormality detected . | MDS . | Follow up abnormality detection, mo . | Survival from diagnosis, mo . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 800 | CCyR | CMR | 18 | t(X;17)(q22;q36) | 1 | 1 | No | 24 | 32 |
| 2 | 800 | CCyR | MMR | 12 | t(15;16)(q15;q24) | 1 | 1 | No | 18 | 30 |
| 3 | 800 | CCyR | CMR | 21 | t(11;17) | 1 | 1 | No | 12 | 33 |
| 4 | 800 | CCyR | MMR | 12 | +X | 1 | 1 | No | 12 | 24 |
| 5 | 800 | CCyR | MMR | 21 | −Y | 1 | 1 | No | 12 | 33 |
| 6 | 800 | CCyR | NA | 27 | del (20) (q11.2) | 1 | 1 | No | 12 | 39 |
| 7 | 400 | CCyR | NA | 21, 27 | del (7) (q22), +8 | 1, 6 | 1, 2 | No | 39, 33 | 60 |
| 8 | 400 | CCyR | MMR | 36 | del (13) (q12q22) | 2 | 1 | No | 15 | 51 |
| 9 | 400 | CCyR | NA | 24, 36 | +8, +6 | 2, 2 | 1, 2 | No | 33, 21 | 57 |
| 10 | 400 | CCyR | CMR | 15 | −Y | 4 | 1 | No | 45 | 60 |
| 11 | 400 | CCyR | MMR | 42 | −Y | 4 | 2 | No | 18 | 60 |
| 12 | 800 | CCyR | MMR | 6 | −Y | 4 | 1 | No | 6 | 12 |
| 13 | 400 | CCyR | MMR | 36 | −Y | 7 | 5 | No | 24 | 60 |
| 14 | 800 | CCyR | MMR | 24 | del (20) (q12) | 2 | 1 | No | 12 | 36 |
| 15 | 800 | CCyR | MMR | 9 | del (7) (q22q34) | 2 | 1 | No | 15 | 24 |
| 16 | 400 | PCyR | NA | 12 | +8 | 2 | 1 | No | 45 | 57 |
| 17 | 800 | mCyR | NA | 6 | −Y | 3 | 3 | No | 36 | 42 |
| 18 | 800 | PCyR | NA | 3 | −Y | 7 | 2 | No | 3 | 6 |
| 19 | 800 | CCyR | CMR | 24 | −Y | 4 | 1 | No | 24 | 48 |
| 20 | 800 | CCyR | MMR | 3 | −Y | 13 | 4 | No | 9 | 12 |
| 21 | 400 | CCyR | NA | 6 | −7 | 20 | 2 | Yes | 6 | 12 |
CMR indicates complete molecular response; t, translocation; NA, not applicable; del, deletion; CCyR, complete cytogenetic response; PCyR, partial cytogenetic response; mCyR, minor cytogenetic response; MMR, major molecular response; and MDS, myelodysplastic syndromes.